Uk Scientists Developing Ebola Vaccine That Could Be Ready For Trials In Months
img_tag = ("A new strain of Ebola that kills one in every three people infected could soon have its first vaccine, as UK scientists race against time to develop protection against the deadly Bundibugyo variant.
Researchers at Oxford University are working on a vaccine specifically targeting the Bundibugyo species of Ebola, which currently has no proven protection and could potentially reach Kenya through our porous borders with Uganda and South Sudan. The team expects to begin human trials within months, marking a critical breakthrough in fighting a virus that has claimed thousands of lives across East Africa.
This development hits close to home for Kenyans who remember the 2014 Ebola outbreak that sent shockwaves across the continent. Our government had to install thermal screening equipment at Jomo Kenyatta International Airport and train health workers at county hospitals to identify suspected cases. Matatu operators and boda boda riders along border towns like Malaba lived in constant fear of unknowingly transporting infected passengers.
The Bundibugyo strain first emerged in Uganda's Bundibugyo district in 2007, killing 37 people out of 116 infected. Unlike other Ebola variants for which vaccines exist, this particular species has remained without protection, making it a ticking time bomb for the region. Kenya's proximity to Uganda means any outbreak there could easily spill over through our shared border, affecting traders, truck drivers, and communities that depend on cross-border business.
County governments in Western Kenya have been particularly vulnerable, with limited resources to handle such health emergencies. During previous scares, residents in places like Busia and Bungoma had to rely on M-Pesa transfers from relatives in Nairobi just to access basic protective equipment. The economic disruption alone from border closures could cripple families who depend on daily cross-border trade.
The Oxford vaccine uses similar technology to their successful COVID-19 shot, giving health experts confidence it could work effectively. If trials prove successful, Kenya would likely be among the first African countries to receive doses, given our strong healthcare partnerships with the UK and our role as a regional medical hub.
But the big question remains: will this vaccine reach ordinary Kenyans in remote counties quickly enough when the next outbreak strikes, or will we once again watch helplessly as the wealthy nations stockpile protection while Africa waits?